AAC

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

Retrieved on: 
Thursday, April 4, 2024
Health, Neurology, Genetics, Pharmaceutical, Optical, Biotechnology, PIII, URD, Three-body problem, Patient, Good manufacturing practice, Health care, EAP, Acquisition, EMA, Risk, Chapter, GMP, MHRA, DS, ATU, AMF, Good, Phase, AAP, Ethics, FDA, Amendment, AAC, Medication, Pharmaceutical industry

GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.

Key Points: 
  • GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.
  • Once the AAC/AAP program resumes, the Company estimates that the cash runway would be extended to the end of Q1 2025.
  • GenSight successfully manufactured two Drug Substance (DS) batches of LUMEVOQ® meeting Good Manufacturing Practice (GMP) standards in September and November 2023.
  • As of March 31, 2024, GenSight Biologics’ number of outstanding shares was 78,370,724 ordinary shares.

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results

Retrieved on: 
Friday, March 22, 2024
Health, Neurology, Genetics, Pharmaceutical, Optical, Biotechnology, Control, URD, Three-body problem, Safety, Partnership, Research, CIR, ANSM, CMC, EMA, BofA Securities, Risk, Chapter, MHRA, Clinical trial, European Investment Bank, ATU, AMF, Workforce, EIB, AAP, Marketing, FDA, Amendment, AAC, Cryptocurrency

From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.

Key Points: 
  • From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.
  • The Company's general and administrative expenses also remained stable and amounted to €5.4 million in 2022 and 2023.
  • The weighted average number of shares outstanding increased from 46.3 million in 2022 to 48.3 million in 2023, thereby reducing the loss per share from (€0.54) in 2023 to (€0.60) in 2023.
  • GenSight Biologics will report its cash position as of March 31, 2024 on April 4 2024.

GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

Retrieved on: 
Tuesday, March 12, 2024
Research, Neurology, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Mutation, Disease, Nadir, Patient, CRR, Eye, Idebenone, Natural history, Phase, Multimedia, Neuro-ophthalmology, ND4, Interval (mathematics), AAC, Medical imaging

The meta-analyses are the first to focus solely on patients with the m.11778G>A ND4 mutation, which is the most common mutation and one with a poor visual prognosis1.

Key Points: 
  • The meta-analyses are the first to focus solely on patients with the m.11778G>A ND4 mutation, which is the most common mutation and one with a poor visual prognosis1.
  • This gradient of recovery, based on the CRR measure of visual improvement, is observed at both eye level and patient level (response in one or both eyes).
  • There is no overlap in confidence intervals when LUMEVOQ® is compared to idebenone and to natural history, indicating a positive difference in visual outcomes.
  • Follow-up of patients in the Phase III REFLECT study of LUMEVOQ® is ongoing, with topline results at Year 4 of follow-up expected this month.

AAC Technologies' Revenue in 2024 is Expected to Increase by 10-15%, PSS Automotive Business Revenue will Exceed RMB3 Billion

Retrieved on: 
Thursday, March 28, 2024
Financial management, Conference, Algorithm, Growth, PSS, CFO, XR, Capital expenditure, Acquisition, WLG, ASP, OEM, AAC Technologies, Yoy, Acoustics, Lens, Multimedia, AAC, Video game

The overall revenue is expected to increase by 10% to 15% in 2024, and the comprehensive gross profit margin will also recover to over 20%.

Key Points: 
  • The overall revenue is expected to increase by 10% to 15% in 2024, and the comprehensive gross profit margin will also recover to over 20%.
  • It is expected that the automotive business will contribute RMB3 to 3.5 billion in revenue, achieving a net profit of around RMB0.2 billion.
  • PSS covers the majority of high-end European and American automotive brands and leads in both customer relations and product innovation.
  • "We expect PSS to contribute RMB3 to 3.5 billion in revenue this year, achieving around RMB2 billion in net profit," Ms. Guo said.

Ambulatory Management Solutions Rebrands to Ambulatory Anesthesia Care (AAC)

Retrieved on: 
Tuesday, March 26, 2024
Health, Anesthesia, EMR, Patient, Accreditation, Acquisition, Credentialing, MD, Quality of life, MBA, Anesthetic, MSO, AMS, Patient safety, CMO, Marketing, Pacific Northwest, AAC, Nursing

CHICAGO, March 26, 2024 /PRNewswire/ -- Ambulatory Anesthesia Care—formerly Ambulatory Management Solutions—began in 2007 when Chicago's Mobile Anesthesiologists, a pioneer of office-based anesthesia in operation since 1996, brought business services in-house.

Key Points: 
  • CHICAGO, March 26, 2024 /PRNewswire/ -- Ambulatory Anesthesia Care—formerly Ambulatory Management Solutions—began in 2007 when Chicago's Mobile Anesthesiologists , a pioneer of office-based anesthesia in operation since 1996, brought business services in-house.
  • AMS, now AAC, has continued to grow and help its practice partners set a new national standard in office-based anesthesia and perioperative services.
  • CEO Scott Mayer noted, "AAC has a unique approach to both ambulatory anesthesia, and healthcare.
  • Dr. Marlon Michel, MBA, founder, M2 Anesthesia , continued, "M2 Anesthesia has been delivering anesthetics to the Pacific Northwest's pediatric dental patients since 2009.

Jonathan Alger, Experienced and Visionary Higher Education Leader, Named 16th President of American University

Retrieved on: 
Monday, March 18, 2024
Civic, Faculty, Learning, Social justice, James Madison University, Phi Beta Kappa, Civil and political rights, Humour, Rutgers University, FBS, American Council, JMU, Democracy, Education, Swarthmore College, R2, ACE, NCAA, Policy, OCR, Supreme court, College, Senate, Public policy, Journal, Research, Student, Social, Publication, Supreme, Family, AAC, Conference, American University, Trustee, Knight Commission, Task force, Heart, Sun Belt Conference, JD, Harvard Law School, Hall, Management

WASHINGTON, March 18, 2024 /PRNewswire/ -- After a competitive national search, American University named Jonathan (Jon) Alger as the institution's 16th president. Alger comes to AU after 12 years as president of James Madison University (JMU) in Harrisonburg, Virginia. Alger will join AU on July 1, 2024, when current President Sylvia Burwell concludes seven changemaking years leading the institution to extensive impact.

Key Points: 
  • Nationally recognized higher education policy scholar led James Madison University for 12 years, transforming the institution's academic, community, and athletic profile
    WASHINGTON, March 18, 2024 /PRNewswire/ -- After a competitive national search, American University named Jonathan (Jon) Alger as the institution's 16th president.
  • "His vision for American University, his understanding of the unique attributes of a university community, and his proven ability to address the complex challenges facing higher education have prepared Jon to lead American University moving forward."
  • Higher education leaders praised Alger's leadership and his selection as American University's 16th president:
    "Jon Alger's experience in higher education generally and especially his extraordinarily successful tenure as president of James Madison University makes him an outstanding choice to lead American University.
  • He will bring his extensive substantive expertise, strong leadership skills, and immense knowledge of higher education to American University as its next president.

Bierman Autism Centers Elevates Inclusive Play at Eatontown's 80 Acre Park with AAC Board Donation

Retrieved on: 
Thursday, February 22, 2024
AAC, Marketing, Autism spectrum, Calendar, Augmentative and alternative communication, Communication, Family, Bierman, Child, Spectrum

Eatontown, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- In a heartwarming gesture of inclusivity, Bierman Autism Centers (Bierman) announces the donation of an Augmentative and Alternative Communication (AAC) Board to the Borough of Eatontown, NJ .

Key Points: 
  • Eatontown, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- In a heartwarming gesture of inclusivity, Bierman Autism Centers (Bierman) announces the donation of an Augmentative and Alternative Communication (AAC) Board to the Borough of Eatontown, NJ .
  • "Working with Bierman Autism Centers has been an absolute pleasure.
  • "Our donation of the AAC Communication Board is more than a contribution; it's a reflection of our core values," explained Chrissy Barosky, Chief Clinical Officer.
  • The AAC board in 80 Acre Park is an interactive tool that aids non-verbal children or those with speech difficulties in communicating.

GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024

Retrieved on: 
Wednesday, March 6, 2024
Health, Neurology, Genetics, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, AAC, Doctor of Philosophy, Multimedia, MD, Inflammation, Mendelian traits in humans, EAPS, Visual acuity, Safety, Q3, University, LHON, ND4, Patient, EAP

In both groups, the clinical improvement exceeded the conventional definition of clinical meaningfulness, in which a 15-letter gain is considered meaningful.

Key Points: 
  • In both groups, the clinical improvement exceeded the conventional definition of clinical meaningfulness, in which a 15-letter gain is considered meaningful.
  • The safety profile of the gene therapy continues to be favorable and comparable between bilaterally treated patients and unilaterally treated patients.
  • “Witnessing results like these energizes the GenSight team’s drive to restore early access availability for eligible patients by Q3 this year,” said Laurence Rodriguez, Chief Executive Officer of GenSight.
  • The Company aims to resume early access in France under the Autorisation de l’accès compassionnel (AAC) program in Q3 2024.

THE GENIUS OF PLAY™ MARKS DEVELOPMENTAL DISABILITIES AWARENESS MONTH WITH LAUNCH OF "LET'S PLAY - A PLAYBOOK FOR ALL ABILITIES"

Retrieved on: 
Friday, March 1, 2024
AAC, Caregiver, Toy Association, Playbook, Marketing, Kid, Disability studies, Genius, Augmentative and alternative communication, Social, Learning, Toy, Gesture, All, Child, Shoe, Research, Partnership

"Our extensive research has found that play is crucial for children's cognitive, physical, social, and emotional development.

Key Points: 
  • "Our extensive research has found that play is crucial for children's cognitive, physical, social, and emotional development.
  • There are also alternative ways to play depending on physical limitations, developmental disabilities, and family schedules (i.e., adapting the activity to play in the car, during bathtime, etc.).
  • "Playfulness is a state of mind that transcends our stresses and fosters a sense of joy and well-being," said Llull.
  • The Genius of Play's " Let's Play - A Playbook for Kids of All Abilities " is free to download online in a digital book format.

ZIPS Highlights Hometown Star and Memphis Tigers Women's Basketball Guard, Madison Griggs in "Car Wash Convos™"

Retrieved on: 
Thursday, February 29, 2024
AAC, Social media, Basketball, Obsessions, University, Learfield, Tiger, NIL, Face, Music

MEMPHIS, Tenn., Feb. 29, 2024 /PRNewswire/ -- ZIPS Car Wash (zipscarwash.com) unveiled its latest episode of "Car Wash Convos™" today featuring Madison Griggs, University of Memphis Women's Basketball guard.

Key Points: 
  • MEMPHIS, Tenn., Feb. 29, 2024 /PRNewswire/ -- ZIPS Car Wash (zipscarwash.com) unveiled its latest episode of "Car Wash Convos™" today featuring Madison Griggs, University of Memphis Women's Basketball guard.
  • Madison is interviewed alongside host Sydney Neely, Memphis Tigers In-Arena Host.
  • "Car Wash Convos is a really cool, alternative approach to NIL and I'm proud to be a part of it representing my school and my hometown, especially alongside other accomplished student-athletes," said Madison Griggs.
  • Visit the App Store or Google Play from your mobile device and search 'ZIPS Car Wash' to start earning wash rewards and app-only deals.